Cited 0 times in
Cited 0 times in
Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 최진섭 | - |
dc.contributor.author | 최기홍 | - |
dc.contributor.author | 김남규 | - |
dc.contributor.author | 백승혁 | - |
dc.contributor.author | 민병소 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 정민규 | - |
dc.contributor.author | 신상준 | - |
dc.date.accessioned | 2025-08-14T05:03:19Z | - |
dc.date.available | 2025-08-14T05:03:19Z | - |
dc.date.issued | 2013-11 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/207022 | - |
dc.description.abstract | Background: Converting chemotherapy followed by surgery is known to be associated with improved clinical outcomes in colorectal cancer (CRC) patients with hepatic metastasis. This study is to investigate the clinicopathological prognostic factors for disease-free survival (DFS) after curative resection of primary and metastatic lesions. Methods: We retrospectively analyzed the medical records of 76 CRC patients who had initially had unresectable hepatic metastasis, which was considered resectable after systemic chemotherapy, and had undergone curative surgery in the period from January 2006 to December 2011. DFS was compared by assessing clinical data including age, sex, staging, number of hepatic lesion(s), size of the largest hepatic lesion and serum carcinoembryonic antigen (CEA) levels. Results: The median age was 57 years and 47 patients were male. The median DFS was 10.4 months. Multivariate Cox regression analysis revealed that age <50 years (HR 2.70, 95% CI 1.43-5.10, p = 0.002) and CEA elevation after curative surgery (HR 2.20, 95% CI 1.11-4.36, p = 0.023) were associated with a shorter DFS. Conclusions: Given that patients <50 years old or with elevated CEA levels after curative surgery demonstrated a short DFS, additional postoperative systemic treatment or active surveillance, at least, should strongly be considered for this group. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Karger | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antibodies, Monoclonal, Humanized / administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / administration & dosage | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / therapeutic use* | - |
dc.subject.MESH | Bevacizumab | - |
dc.subject.MESH | Biomarkers, Tumor / blood* | - |
dc.subject.MESH | Camptothecin / administration & dosage | - |
dc.subject.MESH | Camptothecin / analogs & derivatives | - |
dc.subject.MESH | Carcinoembryonic Antigen / blood* | - |
dc.subject.MESH | Cetuximab | - |
dc.subject.MESH | Colectomy* | - |
dc.subject.MESH | Colorectal Neoplasms / drug therapy | - |
dc.subject.MESH | Colorectal Neoplasms / mortality | - |
dc.subject.MESH | Colorectal Neoplasms / pathology* | - |
dc.subject.MESH | Colorectal Neoplasms / surgery | - |
dc.subject.MESH | Colorectal Neoplasms / therapy* | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil / administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Leucovorin / administration & dosage | - |
dc.subject.MESH | Liver Neoplasms / drug therapy | - |
dc.subject.MESH | Liver Neoplasms / mortality | - |
dc.subject.MESH | Liver Neoplasms / secondary* | - |
dc.subject.MESH | Liver Neoplasms / surgery | - |
dc.subject.MESH | Liver Neoplasms / therapy* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Neoadjuvant Therapy / methods* | - |
dc.subject.MESH | Neoplasm Staging | - |
dc.subject.MESH | Organoplatinum Compounds / administration & dosage | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Proportional Hazards Models | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Risk Assessment | - |
dc.subject.MESH | Risk Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Jun Ho Yi | - |
dc.contributor.googleauthor | Hyunki Kim | - |
dc.contributor.googleauthor | Minkyu Jung | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Jin Sub Choi | - |
dc.contributor.googleauthor | Gi-Hong Choi | - |
dc.contributor.googleauthor | Seung Hyuk Baik | - |
dc.contributor.googleauthor | Byung Soh Min | - |
dc.contributor.googleauthor | Nam Kyu Kim | - |
dc.contributor.googleauthor | Joong Bae Ahn | - |
dc.identifier.doi | 10.1159/000355475 | - |
dc.contributor.localId | A04199 | - |
dc.contributor.localId | A04046 | - |
dc.contributor.localId | A00353 | - |
dc.contributor.localId | A01827 | - |
dc.contributor.localId | A01402 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A03606 | - |
dc.contributor.localId | A02105 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | 24217184 | - |
dc.identifier.url | https://karger.com/ocl/article/85/5/283/239072/Prognostic-Factors-for-Disease-Free-Survival-after | - |
dc.contributor.alternativeName | Choi, Jin Sub | - |
dc.contributor.affiliatedAuthor | 최진섭 | - |
dc.contributor.affiliatedAuthor | 최기홍 | - |
dc.contributor.affiliatedAuthor | 김남규 | - |
dc.contributor.affiliatedAuthor | 백승혁 | - |
dc.contributor.affiliatedAuthor | 민병소 | - |
dc.contributor.affiliatedAuthor | 안중배 | - |
dc.contributor.affiliatedAuthor | 정민규 | - |
dc.contributor.affiliatedAuthor | 신상준 | - |
dc.citation.volume | 85 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 283 | - |
dc.citation.endPage | 289 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.85(5) : 283-289, 2013-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.